Tag: AOBiome Therapeutics

AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)
Uncategorized

AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)

B244, a first-in-class topical live biotherapeutic product, is currently planned for global Phase 3 development in mild to moderate atopic dermatitis and pruritus. EMA’s Pediatric Committee (PDCO) agrees to AOBiome’s PIP with a positive decision […]

Continue Reading →